Physician profile
Richard A Blake
NPI 1699702308
$4,960.32
in general payments reported to CMS, 2019-2025
22 companies · $538 in 2025
The $538 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $981 · 2020: $313 · 2021: $607 · 2022: $694 · 2023: $1,003 · 2024: $825 · 2025: $538.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,366.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,365.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $650.54 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $642.95 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $528.34 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $491.37 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $465.66 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $452.33 | 2021-2025 | Verquvo |
| Medtronic Vascular, INC. | $257.72 | 2019 | |
| Medtronic, INC. | $225.82 | 2023-2024 | Azure Xt Dr Mri Surescan, Micra |
| Abiomed | $209.92 | 2024-2025 | Impella |
| Esperion Therapeutics, INC. | $201.37 | 2021-2025 | Nexletol |
| Janssen Scientific Affairs, LLC | $196.42 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $155.33 | 2023-2025 | Brilinta |
| Bayer Healthcare Pharmaceuticals INC. | $135.18 | 2022 | |
| Allergan, INC. | $118.18 | 2019-2020 | |
| Irhythm Technologies, INC. | $70.00 | 2022-2024 | Zio Xt Patch, Zio Monitor |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $46.29 | 2019-2023 | Lifevest |
| Atricure, INC. | $30.19 | 2023-2024 | |
| Abbott Laboratories | $24.40 | 2021 | |
| Lundbeck LLC | $16.62 | 2019 | |
| Boston Scientific Corporation | $16.24 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.95 | 2020 | |
| Bardy Diagnostics, INC. | $12.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Blake listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.